Theravance Biopharma (NASDAQ:TBPH) Cut to Buy at Wall Street Zen

Theravance Biopharma (NASDAQ:TBPH) was downgraded by analysts at Wall Street Zen from a “strong-buy” rating to a “buy” rating in a report issued on Monday.

Several other equities research analysts have also commented on the stock. TD Cowen upped their price target on shares of Theravance Biopharma from $13.00 to $15.00 and gave the company a “hold” rating in a research report on Monday, March 23rd. Zacks Research upgraded shares of Theravance Biopharma from a “hold” rating to a “strong-buy” rating in a research report on Thursday, March 19th. BTIG Research reaffirmed a “buy” rating and set a $21.00 target price on shares of Theravance Biopharma in a report on Friday, March 20th. HC Wainwright increased their price target on shares of Theravance Biopharma from $20.00 to $27.00 and gave the stock a “buy” rating in a research report on Monday, March 2nd. Finally, Oppenheimer cut shares of Theravance Biopharma from an “outperform” rating to a “market perform” rating in a research note on Thursday, March 5th. Two research analysts have rated the stock with a Strong Buy rating, three have issued a Buy rating and three have issued a Hold rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $21.33.

Theravance Biopharma Stock Performance

TBPH stock opened at $16.02 on Monday. The company has a market cap of $824.87 million, a price-to-earnings ratio of 7.89 and a beta of 0.17. The business’s 50-day moving average is $17.05 and its two-hundred day moving average is $16.99. Theravance Biopharma has a fifty-two week low of $7.90 and a fifty-two week high of $21.03.

Insider Activity at Theravance Biopharma

In other news, SVP Rhonda Farnum sold 31,067 shares of Theravance Biopharma stock in a transaction dated Monday, March 16th. The stock was sold at an average price of $13.96, for a total transaction of $433,695.32. Following the transaction, the senior vice president directly owned 232,699 shares of the company’s stock, valued at $3,248,478.04. The trade was a 11.78% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. 6.90% of the stock is owned by company insiders.

Institutional Investors Weigh In On Theravance Biopharma

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the company. AQR Capital Management LLC purchased a new position in Theravance Biopharma during the first quarter valued at approximately $101,000. Jane Street Group LLC increased its stake in shares of Theravance Biopharma by 169.2% in the first quarter. Jane Street Group LLC now owns 140,884 shares of the biopharmaceutical company’s stock worth $1,258,000 after purchasing an additional 88,540 shares in the last quarter. Creative Planning purchased a new stake in shares of Theravance Biopharma in the second quarter worth $139,000. American Century Companies Inc. raised its position in shares of Theravance Biopharma by 6.8% during the 2nd quarter. American Century Companies Inc. now owns 91,501 shares of the biopharmaceutical company’s stock valued at $1,009,000 after purchasing an additional 5,794 shares during the period. Finally, Hsbc Holdings PLC bought a new stake in shares of Theravance Biopharma during the 2nd quarter valued at $638,000. 99.10% of the stock is owned by hedge funds and other institutional investors.

About Theravance Biopharma

Theravance Biopharma is a biopharmaceutical company focused on the discovery, development and commercialization of innovative medicines, primarily in the areas of respiratory disease, inflammatory and immunology, and rare disorders. The company develops small-molecule therapies designed to address unmet medical needs by targeting specific molecular pathways. Its lead marketed product, YUPELRI® (revefenacin) inhalation solution, is the first and only once-daily, long-acting muscarinic antagonist (LAMA) approved by the U.S.